Eli Lilly and Company

05/24/2022 | Press release | Distributed by Public on 05/24/2022 01:07

Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study